A phase Ia trial of single ascending doses of MIV 711 in healthy volunteers
Latest Information Update: 05 Jun 2013
Price :
$35 *
At a glance
- Drugs MIV 711 (Primary)
- Indications Bone metastases; Osteoarthritis; Osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 21 May 2013 Promising outcomes reported at the European Calcified Tissue Society (ECTS) Annual Meeting, according to a Medivir media release.
- 22 Aug 2012 Status changed from recruiting to completed, according to a Medivir AB media release.
- 28 May 2012 Status changed from planning to recruiting according to a Medivir media release.